Search results
Results from the WOW.Com Content Network
Glycopeptide antibiotics are a class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides.Significant glycopeptide antibiotics include the anti-infective antibiotics vancomycin, teicoplanin, telavancin, ramoplanin, avoparcin and decaplanin, corbomycin, complestatin and the antitumor antibiotic bleomycin.
Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections. [7] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. [8]
Antibiotics by class Generic name Brand names Common uses [4] Possible side effects [4] Mechanism of action Aminoglycosides; Amikacin: Amikin: Infections caused by Gram-negative bacteria, such as Escherichia coli and Klebsiella particularly Pseudomonas aeruginosa. Effective against aerobic bacteria (not obligate/facultative anaerobes) and ...
Narrow-spectrum antibiotics have low propensity to induce bacterial resistance and are less likely to disrupt the microbiome (normal microflora). [3] On the other hand, indiscriminate use of broad-spectrum antibiotics may not only induce the development of bacterial resistance and promote the emergency of multidrug-resistant organisms, but also cause off-target effects due to dysbiosis.
Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU (both by AbbVie) among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus ...
Class: Actinomycetia: ... including the antibiotic drug vancomycin. [3] [4] ... The antibiotic vancomycin was first isolated from the bacteria in 1953. [4] [5]
Quinupristin and dalfopristin are protein synthesis inhibitors in a synergistic manner. While each of the two is only a bacteriostatic agent, the combination shows bactericidal activity.
Telavancin is a semi-synthetic derivative of vancomycin. [1] [2] The FDA approved the drug in September 2009 for complicated skin and skin structure infections (cSSSI), [3] and in June 2013 for hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. [4]